On the stock market since 2010, it operates in the world of health and science. It has 65,694 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
The gap is $3.6B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
It pays out $0.84 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 3% a year on average. At this size, speeding back up is not easy.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, ERFSF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ERFSF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.